BrainsWay Deep TMS Shows Strong Efficacy in Largest Real-World Study for Comorbid PTSD and Depression

summarizeSummary

BrainsWay announced positive real-world data from the largest study to date, showing significant improvements in patients with comorbid PTSD and Major Depressive Disorder treated with its Deep TMS technology.

check_boxKey Events · Product Development and Regulatory · BWAY

• Positive Real-World Study Results

  Deep TMS demonstrated an 83.5% response rate for PTSD symptoms and a 66.6% response rate for depression symptoms in patients with comorbid PTSD and MDD.

• Significant Symptom Reduction

  Patients experienced an average 52% reduction in PTSD symptoms (PCL-5 scores) and a 50% reduction in depression symptoms (PHQ-9 scores).

• Largest Study to Date

  The findings come from the largest real-world study of Deep TMS for this comorbid condition, involving 462 patients across 11 clinical sites.

• Future Indication Potential

  While not yet FDA-cleared for this specific indication, these positive results support the potential for future regulatory expansion and market growth.

auto_awesomeAnalysis · BWAY · Industrial Applications And Services

This filing highlights promising clinical results for BrainsWay's Deep TMS technology in a challenging patient population with both PTSD and major depressive disorder. While Deep TMS is not yet FDA-cleared for this specific comorbid indication, the strong response rates from a large real-world study (83.5% for PTSD symptoms, 66.6% for depression symptoms) provide compelling evidence for its potential. This data strengthens the company's product pipeline and supports future efforts to expand regulatory clearances, potentially opening up a significant new market for its technology.